Lipitor (Atorvastatin)

Atorvastatin (Lipitor) is used to manage disorders of lipid metabolism and to reduce cardiovascular risk.

• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol in patients with elevated cholesterol levels.
• Mixed dyslipidemia: improves the overall lipid profile by lowering triglycerides and raising HDL‑cholesterol.
• Primary prevention of cardiovascular disease: lowers the risk of heart attack and stroke in high‑risk individuals.
• Secondary prevention of cardiovascular events: helps prevent recurrent myocardial infarction or stroke in patients with established disease.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in the hepatic synthesis of cholesterol. By blocking this rate‑limiting step, intracellular cholesterol production declines, prompting up‑regulation of LDL receptors and increased clearance of circulating LDL particles, thereby lowering plasma LDL‑cholesterol, total cholesterol, and triglyceride concentrations.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects

• Headache: mild to moderate pain often reported during early treatment.
• Myalgia: muscle aches without weakness, frequently observed.
• Gastrointestinal discomfort: includes nausea, abdominal pain or constipation.
• Elevated liver enzymes: mild increases in ALT or AST levels.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to renal failure.
• Acute liver injury: marked elevation of liver enzymes or jaundice.
• Severe allergic reactions: including rash, angioedema, or anaphylaxis.
• Myopathy with weakness: significant muscle weakness accompanied by pain.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

Use of atorvastatin requires careful consideration of several safety factors.

• Pregnancy: contraindicated (Category X) due to risk of fetal harm; avoid use in pregnant women.
• Liver disease: assess hepatic function before initiation and monitor periodically.
• Renal impairment: dose adjustment may be necessary in patients with severe renal dysfunction.
• Drug interactions: review concomitant medications for potential interactions that increase myopathy risk.
• Monitoring: obtain baseline and periodic liver enzyme tests during therapy.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Atorvastatin can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase atorvastatin plasma levels.
• Grapefruit juice: markedly raises drug exposure and risk of muscle toxicity.
• Gemfibrozil: synergistic effect on myopathy and rhabdomyolysis.
• High‑dose colchicine: elevates risk of severe muscle injury.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance hypotensive effects.
• Warfarin: can increase INR and bleeding risk.
• Niacin: may raise the likelihood of liver enzyme elevations.